By W. Schramm, H. Krebs (auth.), Professor Dr. med. Inge Scharrer, Professor Dr. med. Wolfgang Schramm (eds.)
Read Online or Download 33rd Hemophilia Symposium: Hamburg 2002 PDF
Similar nonfiction_10 books
The chemistry of transition steel carbyne complexes has turn into a hugely beautiful box prior to now 20 years. in recent times its program to elements of catalysis and metathesis has won enormous curiosity from inorganic in addition to natural chemists. furthermore, natural synthesis by way of steel carbon a number of bond reagents bargains the main refined expertise presently to be had.
- Biochemical Actions of Hormones. Volume 6
- Molecular Cytogenetics
- Cardiac-Vascular Remodeling and Functional Interaction
- Problems in Gynaecology
Additional info for 33rd Hemophilia Symposium: Hamburg 2002
Residues 484–508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 1995; 270: 14505–14509 Saenko EL, Ananyeva NM, Kouiavskaia DV, Khrenov AV, Anderson JA, Shima M, Qian J,Scott D. Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action. Haemophilia 2002; 8: 1-11 Fulcher CA, de Graaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS. Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments.
Oppermann, Elisabeth Holfeld, Dagmar Möbius, Cottbus; Johann Böhmann, Claudia Niekrens, Delmenhorst; Joachim Mößeler, Dillingen; Wolfgang Kotte, Heiner Güldenring, Dresden; Jörg Wendisch, Dresden; Heiner Trobisch, Duisburg; U. Göbel, Lex, Düsseldorf; G. Vogel, Frau Winterstein, Erfurt; Jens Klinge, M. Girisch, Erlangen; R. Eckstein, Erlangen; Christian Klinkenstein, Frankfurt (Oder); Frau I. Scharrer, Frankfurt/Main; W. Kreuz, Klarmann, Frankfurt/Main; W. H. Sutor, Barbara Ziegler, Freiburg; R.
15 days later we documented relapse of the acquired hemophilia and bleeding episodes. The factor VIII level was 4% and factor VIII inhibitor max. 9 BU. The patient received four weekly doses of Rituximab therapy at 375 mg/m2 per week. Temporary immunosuppression was achieved with steroids (100 mg/day) and, recurrent soft tissue bleedings were treated with recombinant activated factor VII. 6 days after completion of the therapy, the factor VIII level was 73% and factor VIII inhibitor titre 0 BU.
33rd Hemophilia Symposium: Hamburg 2002 by W. Schramm, H. Krebs (auth.), Professor Dr. med. Inge Scharrer, Professor Dr. med. Wolfgang Schramm (eds.)